Original article
Venom immunotherapy: 10 years of experience with administration of single venoms and 50 μg maintenance doses

https://doi.org/10.1016/0091-6749(92)90304-KGet rights and content

Abstract

For the past 10 years, we have administered venom immunotherapy with single venoms, whenever it is possible, and maintenance doses of 50 μg. The choice of venoms was based on clinical history, skin test reactions, and a knowledge of venom cross-reactivity. There have been. 258 re-stings in 108 patients with only three systemic reactions (2.7% per patient; 1.2% per sting). Two of these re-stings reactions were very mild, hives and facial edema, in patients who had had initial severe anaphylaxis. Five other patients had transient ill-defined symptoms, not considered allergic after re-stings. The patients covered a wide age range. Twenty-seven patients, nine under age 16 years, had initial dermal reactions only, and 44 patients had severe anaphylaxis. Most patients had multiple positive skin tests. Seventy-five patients received single venoms (yellow.jacket, 58; honeybee, 15; hornet, 2), and 30 patients received two venoms. Re-stings occurred from 1 month to 8 years, (mean, 2 years) after starting treatment. Results indicate that this approach with 50 μg top doses and single venom immunotherapy may be sufficient in most patients with an associated decrease in the cost as well as possible increased morbidity associated with the use of multiple venom antigens.

References (12)

There are more references available in the full text version of this article.

Cited by (70)

  • Anaphylaxis to Stinging Insect Venom

    2022, Immunology and Allergy Clinics of North America
    Citation Excerpt :

    Mitigation strategies such as the use of EMI or the switch to a different manufacturer’s extracts are both feasible plans. Safety and efficacy of lowered MDs (eg, 50 μg) has been studied and shown to provide good efficacy in children, although the data in adults are conflicting.59–61 Other long-term strategies include improvement in diagnostics such as CRD to ensure that patients are only treated with extracts that are clinically relevant.

  • Venom Immunotherapy: Questions and Controversies

    2020, Immunology and Allergy Clinics of North America

  • Approach to Patients with Stinging Insect Allergy

    2020, Medical Clinics of North America
    Citation Excerpt :

    There is no evidence that there is increased risk of adverse reactions with any specific protocol (other than ultrarush protocols, which can increase the risk of anaphylaxis during buildup dosing).77–80 The maintenance dose is 100 μg of each venom, although in young children there is some evidence that a dose of 50 μg of each venom may be as protective.81–83 Once patients reach maintenance dosing, they usually receive subcutaneous injections every 4 weeks for at least 1 year, then every 6 to 8 weeks for 2 to 3 years, and then every 12 weeks.

  • AAAAI/ACAAI Joint Venom Extract Shortage Task Force Report

    2017, Annals of Allergy, Asthma and Immunology

  • Stinging insect hypersensitivity: A practice parameter update 2016

    2017, Annals of Allergy, Asthma and Immunology
    Citation Excerpt :

    Consensus data on which venoms to include for immunotherapy are not available. In the opinion of some authors, applying a knowledge of venom cross-reactivity and insect identification, the extract used for VIT need only contain a single venom if the culprit is definitively known, despite positive skin or in vitro test results for other stinging insects.50,160 Other authors recommend that the treatment include venoms from all insects for which positive test results were obtained because of the potential for reaction to any venoms to which the patient is sensitized.161,162

  • Cytotoxic, genotoxic/antigenotoxic and mutagenic/antimutagenic effects of the venom of the wasp Polybia paulista

    2013, Toxicon
    Citation Excerpt :

    We highlight, therefore, that it is very difficult to occur exposure to this concentration, since in a single sting of vespids it can be injected into the skin only about 20 μg of the venom. This concentration can, according to Reisman and Livingston (1992), be enough to trigger the sensitization process in human beings. However, from our results the concentration of 20 μg/mL did not induce high cytotoxicity for the exposed cells.

View all citing articles on Scopus
View full text
Copyright © 1992 Published by Mosby, Inc.